Biosimilar Interleukins Global Market Report 2025

Description

Biosimilar interleukins refer to proteins produced by the body's white blood cells, known as leukocytes. These interleukins play a crucial role in regulating immune responses. Laboratory-generated interleukins are utilized as biological response modifiers to fortify the immune system, particularly in cancer treatment.

Various types of biosimilar interleukins include IL-17, IL-23, IL-1, IL-5, IL-6, among others. For instance, Interleukin 17 belongs to the pro-inflammatory cystine knot cytokine family and is produced by a specific subset of T helper cells, known as T helper 17 cells, in response to IL-23 stimulation. These biosimilar interleukins find diverse applications in treating conditions such as psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (IBD), and other immune-related disorders. They are made available through various distribution channels, including hospital pharmacies, online pharmacies, retail pharmacies, clinics, as well as research institutes, catering to different healthcare settings and patient needs.

The biosimilar interleukins market research report is one of a series of new reports from The Business Research Company that provides biosimilar interleukins market statistics, including biosimilar interleukins industry global market size, regional shares, competitors with a biosimilar interleukins market share, detailed biosimilar interleukins market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar interleukins industry. The biosimilar interleukins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biosimilar interleukins market size has grown exponentially in recent years. It will grow from $3.9 billion in 2024 to $5.41 billion in 2025 at a compound annual growth rate (CAGR) of 39.0%. The growth in the historic period can be attributed to the rising prevalence of autoimmune diseases, increasing awareness of biosimilar interleukins, growing government support for biosimilars, expansion of the biosimilar, and increasing patient demand for biosimilars.

The biosimilar interleukins market size is expected to see exponential growth in the next few years. It will grow to $20.79 billion in 2029 at a compound annual growth rate (CAGR) of 40.0%. The growth in the forecast period can be attributed to the growing patient population, increased access to healthcare, growing demand for personalized medicine, and growing demand for minimally invasive procedures. Major trends in the forecast period include advances in biosimilar technology, targeted immunotherapies, quality control and manufacturing, and global collaboration.

The rising prevalence of autoimmune diseases, such as psoriasis and rheumatoid arthritis, is anticipated to enhance the growth of the interleukin biosimilars market during the forecast period. Autoimmune disorders occur when immune cells fail to differentiate between healthy cells and potentially harmful antibodies. Biologic drugs, including anti-interleukin antibodies, have demonstrated significant clinical advantages in regulating these immune cells and managing their proliferation, activation, and migration. For instance, in February 2024, reports from the National Institutes of Health (NIH), a U.S.-based biomedical research agency, indicated that the global incidence and prevalence of autoimmune diseases are projected to increase annually by 19.1% and 12.5%, respectively. As a result, the growing prevalence of autoimmune diseases is driving demand for biosimilar interleukins and is expected to propel market growth.

The increasing prevalence of arthritis is expected to drive the growth of the biosimilar interleukins market. Arthritis refers to pain or inflammation affecting the joints, which can involve swelling in one or more joints. Biosimilars, including interleukins, are utilized in the treatment of various inflammatory and autoimmune disorders such as rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis. For example, in February 2024, reports from the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, indicated that in 2022, the age-adjusted rate of adults living with arthritis was 18.9%. Consequently, the rising prevalence of arthritis is projected to further accelerate the growth of the biosimilar interleukins market in the future.

Key players in the biosimilar interleukins market are introducing innovative products like Tofidence (tocilizumab-bavi) to bolster their profitability in the market. Tofidence, a monoclonal antibody targeting and binding to interleukin-6 receptors, serves in treating various inflammatory autoimmune disorders. In September 2023, Biogen, a US-based biotechnology company, received FDA approval for Tofidence (tocilizumab-bavi) as the initial biosimilar to Genentech's Actemra (tocilizumab). Administered via intravenous infusion, Tofidence has gained approval for treating severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis, marking a strategic move to enhance their market presence and profitability.

In February 2022, Equillium, a biotechnology company based in the United States, acquired Bioniz Therapeutics, Inc. for $329 million. This acquisition significantly expands Equillium's portfolio of innovative immunomodulatory drug candidates by providing access to three established therapeutics and additional assets currently in the discovery phase. Bioniz Therapeutics, Inc. is also a biotechnology company located in the U.S.

Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.

North America was the largest region in the biosimilar interleukins market in 2024. The regions covered in the biosimilar interleukins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The biosimilar interleukins market consists of sales of mabPharm, gedeonrichter, and bio-thera solutions. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biosimilar Interleukins Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biosimilar interleukins market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimilar interleukins ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimilar interleukins market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: IL-17; IL-23; IL-1; IL-5; IL-6
2) By Application: Psoriasis; Psoriatic Arthritis; Rheumatoid Arthritis; Asthma; Inflammatory Bowel Disease (IBD); Other Applications
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Clinics; Research Institutes
Subsegments:
1) By IL-17: Autoimmune Disease Treatment; Inflammatory Disease Management
2) By IL-23: Psoriasis Treatment; Inflammatory Bowel Disease (IBD) Treatment
3) By IL-1: Rheumatoid Arthritis Management; Other Autoimmune Disorders
4) By IL-5: Asthma Treatment; Eosinophilic Disorders
5) By IL-6: Rheumatoid Arthritis Management; Inflammatory Disease Treatment
Companies Mentioned: Mabpharm Limitied; Gedeon Richter plc; Bio-Thera Solutions Ltd.; Sunshine Guojian Pharmaceutical; Stada Arzneimittel AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r32885

1. Executive Summary

2. Biosimilar Interleukins Market Characteristics

3. Biosimilar Interleukins Market Trends And Strategies

4. Biosimilar Interleukins Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Biosimilar Interleukins Growth Analysis And Strategic Analysis Framework

5.1. Global Biosimilar Interleukins PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Biosimilar Interleukins Market Growth Rate Analysis
5.4. Global Biosimilar Interleukins Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Biosimilar Interleukins Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Biosimilar Interleukins Total Addressable Market (TAM)

6. Biosimilar Interleukins Market Segmentation

6.1. Global Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
IL-17
IL-23
IL-1
IL-5
IL-6
6.2. Global Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Psoriasis
Psoriatic Arthritis
Rheumatoid Arthritis
Asthma
Inflammatory Bowel Disease (IBD)
Other Applications
6.3. Global Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Clinics
Research Institutes
6.4. Global Biosimilar Interleukins Market, Sub-Segmentation Of IL-17, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Autoimmune Disease Treatment
Inflammatory Disease Management
6.5. Global Biosimilar Interleukins Market, Sub-Segmentation Of IL-23, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Psoriasis Treatment
Inflammatory Bowel Disease (IBD) Treatment
6.6. Global Biosimilar Interleukins Market, Sub-Segmentation Of IL-1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rheumatoid Arthritis Management
Other Autoimmune Disorders
6.7. Global Biosimilar Interleukins Market, Sub-Segmentation Of IL-5, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Asthma Treatment
Eosinophilic Disorders
6.8. Global Biosimilar Interleukins Market, Sub-Segmentation Of IL-6, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rheumatoid Arthritis Management
Inflammatory Disease Treatment

7. Biosimilar Interleukins Market Regional And Country Analysis

7.1. Global Biosimilar Interleukins Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Biosimilar Interleukins Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biosimilar Interleukins Market

8.1. Asia-Pacific Biosimilar Interleukins Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biosimilar Interleukins Market

9.1. China Biosimilar Interleukins Market Overview
9.2. China Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biosimilar Interleukins Market

10.1. India Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biosimilar Interleukins Market

11.1. Japan Biosimilar Interleukins Market Overview
11.2. Japan Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biosimilar Interleukins Market

12.1. Australia Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biosimilar Interleukins Market

13.1. Indonesia Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biosimilar Interleukins Market

14.1. South Korea Biosimilar Interleukins Market Overview
14.2. South Korea Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biosimilar Interleukins Market

15.1. Western Europe Biosimilar Interleukins Market Overview
15.2. Western Europe Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biosimilar Interleukins Market

16.1. UK Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biosimilar Interleukins Market

17.1. Germany Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biosimilar Interleukins Market

18.1. France Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biosimilar Interleukins Market

19.1. Italy Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biosimilar Interleukins Market

20.1. Spain Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biosimilar Interleukins Market

21.1. Eastern Europe Biosimilar Interleukins Market Overview
21.2. Eastern Europe Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biosimilar Interleukins Market

22.1. Russia Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biosimilar Interleukins Market

23.1. North America Biosimilar Interleukins Market Overview
23.2. North America Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biosimilar Interleukins Market

24.1. USA Biosimilar Interleukins Market Overview
24.2. USA Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biosimilar Interleukins Market

25.1. Canada Biosimilar Interleukins Market Overview
25.2. Canada Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biosimilar Interleukins Market

26.1. South America Biosimilar Interleukins Market Overview
26.2. South America Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biosimilar Interleukins Market

27.1. Brazil Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biosimilar Interleukins Market

28.1. Middle East Biosimilar Interleukins Market Overview
28.2. Middle East Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biosimilar Interleukins Market

29.1. Africa Biosimilar Interleukins Market Overview
29.2. Africa Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biosimilar Interleukins Market Competitive Landscape And Company Profiles

30.1. Biosimilar Interleukins Market Competitive Landscape
30.2. Biosimilar Interleukins Market Company Profiles
- 30.2.1. Mabpharm Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Gedeon Richter plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bio-Thera Solutions Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sorrento Therapeutics Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sunshine Guojian Pharmaceutical Overview, Products and Services, Strategy and Financial Analysis

31. Biosimilar Interleukins Market Other Major And Innovative Companies

31.1. Stada Arzneimittel AG
31.2. Teva Pharmaceutical Industries
31.3. 3SBio Inc.
31.4. Shanghai Fosun Pharmaceuticals
31.5. Biogen Inc.
31.6. Novartis AG
31.7. Pfizer Inc.
31.8. AbbVie Inc.
31.9. Amgen Inc.
31.10. F. Hoffmann-La Roche AG
31.11. Sanofi SA
31.12. Merck & Co. Inc.
31.13. GlaxoSmithKline plc
31.14. Eli Lilly and Company
31.15. AstraZeneca plc

32. Global Biosimilar Interleukins Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biosimilar Interleukins Market

34. Recent Developments In The Biosimilar Interleukins Market

35. Biosimilar Interleukins Market High Potential Countries, Segments and Strategies

35.1 Biosimilar Interleukins Market In 2029 - Countries Offering Most New Opportunities
35.2 Biosimilar Interleukins Market In 2029 - Segments Offering Most New Opportunities
35.3 Biosimilar Interleukins Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer